Cognition Therapeutics, Inc. (CGTX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CGTX price, last 12 months
Key stats
- Previous close
- $0.9508
- Open
- $0.9800
- Day range
- $0.9335 – $0.9800
- 52-week range
- $0.5501 – $2.05
- Volume
- 540.1K
- Avg volume (20 days)
- 403.3K
- Market cap
- $89.1M
Performance
Technicals and fundamentals
About Cognition Therapeutics, Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $89.1M